EGFR and non-small cell lung carcinoma: Resistance of the NSCLC PDX model LXFA 677 to the EGFR inhibitor gefitinib involves mutations and stimulation of several genes, as well as activation of the STAT1, STAT3, MEK1/2, and NF-κB pathways [66].